Biotechnology

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors

March 11, 2025 8:05 AM

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced it has appointed Craig L. Tendler, M.D. to its Board of Directors effective March 10, 2025. "We are honored and thrilled to have Craig join our Board of Directors. His extensive experience in creating and overseeing development plans, including...

Read more

Aspira Women's Health Announces Closing of $1.37 Million Private Placement of Convertible Notes

March 11, 2025 8:00 AM

Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has entered into a securities purchase agreement dated March 6, 2025, pursuant to which the Company has sold and issued an aggregate principal amount of $1.37 million in the form of Senior Secured Convertible Promissory Notes due March 6,...

Read more

Biolog Introduces the RhizoPlate Line: A Game-Changer for Sustainable Agriculture

March 11, 2025 4:00 AM

Biolog, Inc. - a leading provider of phenotypic cellular profiling products, multi-omic microbial identification services, and tools for cultivating anaerobes - is excited to announce the launch of its new RhizoPlate™ line of microplates for rapidly assessing nitrogen fixation and phosphate solubilization in soil bacteria. For companies focused on developing new products for sustainable agriculture, these plates represent an unprecedented...

Read more

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

March 10, 2025 9:00 AM

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Alliance Global Partners (AGP) has issued an analyst update research report entitled "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy, or...

Read more

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

March 10, 2025 9:00 AM

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA, will participate in a fireside chat on Tuesday, March 18, 2025 at 8:30 AM PT at the 37th Annual ROTH Conference being held in Dana Point, CA. In addition to the presentation,...

Read more

Repair Biotechnologies Announces Appointment of Noted Cardiologist Dr. Deepak L. Bhatt to Scientific Advisory Board

March 10, 2025 8:00 AM

Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com/), a biotechnology company developing first-in-class therapies capable of rapidly reducing atherosclerotic plaque, today announced the appointment of Dr. Deepak L. Bhatt as a scientific advisor. "We are pleased to welcome Dr. Deepak L. Bhatt, a noted interventional cardiologist, to our Scientific Advisory Board," said Reason, Chief Executive Officer and Co-Founder of Repair...

Read more

Biovica Signs New Work Order with US Biotech Company for TKa Testing Services

March 10, 2025 3:15 AM

UPPSALA, SE / ACCESS Newswire / March 10, 2025 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in blood-based cancer monitoring, has secured a new work order (WO) valued at SEK 2.5 million for TKa testing services within its Pharma Services business. This marks the third work order signed with this customer, bringing the total value of the three orders to SEK 7 million. The customer, a clinical-stage biotech...

Read more

BioLumic Launches World's First Commercial Light-Activated Seed Traits

March 6, 2025 2:30 PM

BioLumic, the world's only company programming seed traits with light, has launched its first commercial Trait Activation System at Gro Alliance's seed production facility in Cuba City, Wisconsin. This milestone brings the BioLumic proprietary light-based Genetic Expression Trait (xTrait™) technology to the global seed industry, enabling new opportunities for enhanced crop performance. BioLumic's trait activation system treats inbred corn lines...

Read more

Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11

March 6, 2025 8:30 AM

Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th. About Barinthus Biotherapeutics plc Barinthus Biotherapeutics (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates designed to guide the immune system to overcome autoimmunity and chronic infectious diseases. Helping people living with serious...

Read more

Biovica Signs Agreement With Eurobio Scientific Covering 60 Percent of European Market

March 5, 2025 2:10 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, has signed a collaboration agreement with Eurobio Scientific, a leading French group in in vitro specialty medical diagnostics and life sciences, for DiviTum® TKa in Austria, Benelux, France, Germany, Switzerland and the UK. The scope of the agreement covers 60 percent of the total market potential identified as key European markets for Biovica....

Read more

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

March 4, 2025 9:00 AM

POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development of a new AI-driven model designed to improve the diagnosis of Alzheimer's disease (AD) and other causes of dementia. With Alzheimer's accounting for approximately 60-80% of all dementia cases, alongside other conditions such as vascular...

Read more

BRK Technology Accelerates Sustainable Energy Initiatives, Engages With Industry Leaders

March 4, 2025 9:00 AM

BRK Technology is advancing its mission to revolutionize the heavy machinery fuel sector with eco-friendly biofuels. The company is actively collaborating with prominent industry players to explore innovative solutions that enhance efficiency and reduce environmental impact. Recent discussions with leading firms in the industrial and energy sectors highlight BRK Technology's commitment to sustainable progress. These strategic engagements align...

Read more

uBriGene Biosciences Submits Drug Master File for iPSC Reprogramming mRNA-LNP Kit

March 4, 2025 7:00 AM

uBriGene Biosciences (uBriGene), a leading cell and gene therapy CDMO, is pleased to announce the submission of its Drug Master File (DMF) for its innovative iPSC Reprogramming mRNA-LNP Kit. This comprehensive regulatory submission details the manufacturing and characterizations of the iPSC Reprogramming mRNA-LNP Kit. The iPSC Reprogramming mRNA-LNP Kit represents a cutting-edge platform designed to reprogram somatic cells into induced...

Read more

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

March 4, 2025 7:00 AM

BRIDGEWATER, NJ / ACCESS Newswire / March 4, 2025 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both Programmed Death-1 (PD-1) and Vascular Endothelial Growth Factor (VEGF) receptors. Using its proprietary EpiClick™...

Read more

Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program

March 4, 2025 6:30 AM

Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO) to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB, which is the...

Read more

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

February 28, 2025 8:00 AM

IRVINE, CA / ACCESS Newswire / February 28, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today provided a corporate update and reported financial results for the fourth quarter and year-end of 2024. "Throughout 2024, we executed on our primary objectives - the successful submission of our PMA application for the VenoValve®, and the...

Read more

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

February 27, 2025 9:15 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually. Details for the...

Read more

Tex Cycle Closes FY2024 with Revenue of RM36.2 Million

February 27, 2025 6:30 AM

Tex Cycle Technology (M) Berhad ("Tex Cycle" or the "Group"), an established waste management and recycling solutions provider, today announced its financial results for the fourth quarter ended 31 December 2024 ("Q4 FY2024"). The Group recorded a revenue of RM9.3 million and a Profit Before Tax ("PBT") of RM4.5 million in the quarter, bringing its full-year revenue to RM36.2 million and PBT to RM18.0 million. Compared to the fourth quarter of...

Read more

BioInvent International AB: Year-End Report January 1 - December 31, 2024

February 27, 2025 2:30 AM

BioInvent International (STO:BINV) "2024 was a year with several exciting developments reported from across our broad portfolio of clinical programs. We now have two Phase 2 and four Phase 1 trials running in our six clinical programs leveraging the TNFR2 and FcyRIIB targets. Throughout the year, we pursued building our business by expanding our management team and signing important clinical collaboration and supply agreements with key...

Read more

Vicore Pharma Holding Year-End Report 2024

February 27, 2025 2:30 AM

Vicore Pharma Holding (STO:VICO) Stockholm, February 27, 2025 - Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today published the year-end report for 2024. "The fourth quarter was another pivotal period for Vicore as the company successfully raised over SEK 880 million (USD ~85 million) in financing transactions, while ramping up the global,...

Read more